LU90410I2 - Milnacipran (chlorhydrate) - Google Patents

Milnacipran (chlorhydrate)

Info

Publication number
LU90410I2
LU90410I2 LU90410C LU90410C LU90410I2 LU 90410 I2 LU90410 I2 LU 90410I2 LU 90410 C LU90410 C LU 90410C LU 90410 C LU90410 C LU 90410C LU 90410 I2 LU90410 I2 LU 90410I2
Authority
LU
Luxembourg
Prior art keywords
atom
alkyl group
lower alkyl
group
heterocycle
Prior art date
Application number
LU90410C
Other languages
English (en)
French (fr)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9259785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90410(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of LU90410I2 publication Critical patent/LU90410I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LU90410C 1981-06-23 1999-06-30 Milnacipran (chlorhydrate) LU90410I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8112312A FR2508035A1 (fr) 1981-06-23 1981-06-23 Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central

Publications (1)

Publication Number Publication Date
LU90410I2 true LU90410I2 (fr) 1999-08-31

Family

ID=9259785

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90410C LU90410I2 (fr) 1981-06-23 1999-06-30 Milnacipran (chlorhydrate)

Country Status (11)

Country Link
US (1) US4478836A (show.php)
EP (1) EP0068999B1 (show.php)
JP (1) JPS584752A (show.php)
AT (1) ATE13422T1 (show.php)
AU (1) AU550774B2 (show.php)
CA (1) CA1202639A (show.php)
DE (1) DE3263734D1 (show.php)
ES (1) ES512842A0 (show.php)
FR (1) FR2508035A1 (show.php)
LU (1) LU90410I2 (show.php)
ZA (1) ZA824453B (show.php)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581059B1 (fr) * 1985-04-25 1988-04-22 Pf Medicament Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
FR2581060B1 (fr) * 1985-04-25 1988-07-01 Pf Medicament Procede industriel d'obtention du midalcipran
WO1995022521A1 (en) * 1994-02-22 1995-08-24 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivative
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
JP4494015B2 (ja) * 2001-10-12 2010-06-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド β−ラクタミル・バソプレッシンＶ１ａ拮抗剤
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
JP2005523334A (ja) * 2002-04-24 2005-08-04 サイプレス バイオサイエンス， インコーポレイテッド ストレス関連障害を含む機能的身体障害の予防および処置
MXPA05004381A (es) * 2002-10-25 2006-02-10 Collegium Pharmaceutical Inc Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
EP1908461B9 (fr) * 2003-02-14 2011-08-31 Pierre Fabre Medicament Utilisation de l'énantiomère (1S, 2R) du milnacipran pour la préparation d'un médicament
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
MXPA06001738A (es) * 2003-08-15 2006-05-12 Lundbeck & Co As H Derivados de ciclopropilo como antagonistas del receptor nk3.
ZA200601175B (en) * 2003-08-15 2007-04-25 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
JP4418717B2 (ja) * 2004-06-24 2010-02-24 住友化学株式会社 （ｚ）−１−フェニル−１−ジエチルアミノカルボニル−２−アミノメチルシクロプロパン塩酸塩の製造方法
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
AR056980A1 (es) * 2005-04-22 2007-11-07 Wyeth Corp Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
WO2006132307A1 (ja) 2005-06-10 2006-12-14 Pierre Fabre Medicament S.A. 安定化されたミルナシプラン製剤
JP2009500043A (ja) * 2005-07-08 2009-01-08 ブレインセルス，インコーポレイティド 神経新生を調節する薬剤及び条件を同定する方法
BRPI0613664B1 (pt) * 2005-07-19 2021-08-24 Azevan Pharmaceuticals, Inc Compostos antagonistas de beta-lactamil fenilalanina, cisteína e serina vasopressina, composição farmacêutica que compreende ditos compostos e usos terapêuticos dos mesmos
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CN101374552A (zh) * 2006-01-27 2009-02-25 旭化成制药株式会社 经鼻给药用药剂
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007112014A2 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20100145099A1 (en) * 2007-02-28 2010-06-10 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
US20090069431A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched milnacipran
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010036773A1 (en) * 2008-09-24 2010-04-01 Concert Pharmaceuticals, Inc. Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
FR2941454B1 (fr) 2009-01-29 2011-04-01 Pf Medicament Proced de synthese du (1s,2r)-milnacipran
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
US9173845B2 (en) 2009-08-05 2015-11-03 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
EP2496079A4 (en) * 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
WO2011092065A1 (en) 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
ES2858499T3 (es) 2010-07-01 2021-09-30 Azevan Pharmaceuticals Inc Compuestos para su uso en el tratamiento de trastorno explosivo intermitente
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
WO2012059933A1 (en) 2010-11-03 2012-05-10 Arch Pharmalabs Limited A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts.
US20140045936A1 (en) * 2011-04-21 2014-02-13 Wake Forest University Health Sciences Cyclopropyl derivatives and methods of use
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
WO2014203277A2 (en) * 2013-06-19 2014-12-24 Msn Laboratories Private Limited Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride
WO2015044962A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited Amorphous form of levomilnacipran hydrochloride and hydrates thereof
JP7255967B2 (ja) 2014-03-28 2023-04-11 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
TW201919625A (zh) 2017-09-15 2019-06-01 美商愛治凡製藥公司 用於治療腦損傷之組合物及方法
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA619080A (en) * 1961-04-25 The Upjohn Company N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES
CA570688A (en) * 1959-02-17 E. Speeter Merrill Antispasmodic substituted amines
GB1415541A (en) 1972-11-30 1975-11-26 Hexachimie 1-amino-methyl-2,2-diarylcyclopropanecarboxamide

Also Published As

Publication number Publication date
AU550774B2 (en) 1986-04-10
JPS6323186B2 (show.php) 1988-05-16
ATE13422T1 (de) 1985-06-15
FR2508035A1 (fr) 1982-12-24
CA1202639A (fr) 1986-04-01
EP0068999B1 (fr) 1985-05-22
US4478836A (en) 1984-10-23
FR2508035B1 (show.php) 1984-06-29
JPS584752A (ja) 1983-01-11
EP0068999A1 (fr) 1983-01-05
ES8303293A1 (es) 1983-03-01
AU8508682A (en) 1983-01-06
DE3263734D1 (en) 1985-06-27
ES512842A0 (es) 1983-03-01
ZA824453B (en) 1983-04-27

Similar Documents

Publication Publication Date Title
LU90410I2 (fr) Milnacipran (chlorhydrate)
ATE52498T1 (de) Amidderivate.
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
FI943948A0 (fi) Heterosykliset hiilihappojohdannaiset
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
ATE28565T1 (de) Spiro(4.(3+n))-2-aza-alkan-3-carbonsaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung.
DK0637586T3 (da) 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
ID23954A (id) Tetrahidrogama-karbolin
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ES8403122A1 (es) Un procedimiento de preparacion de un compuesto.
DK0526313T3 (da) Nye ureaderivater, deres fremstilling og terapeutiske anvendelse
NO920438D0 (no) N-(aryloksyalkyl)heteroaryl-8-azabicyklo(3.2.1.)oktaner, mellomprodukter og en fremgangsmaate for fremstilling deravsamt anvendelse som medikamenter
ATE121621T1 (de) Verwendung von tetrahydrothienopyridinderivate als angiogenese-inhibitoren.
SE8102220L (sv) Anvendning av substituerade derivat av 4-fenyl-4-oxo-2-butensyra sasom lekemedel
NO304373B1 (no) Imidazol-derivater, farmas°ytiske preparater inneholdende dem og anvendelse av dem
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
NO913543L (no) Fremgangsmaate for fremstilling av 3-(1h-indazol-3-yl)-4-pyridinaminer og mellomprodukter, og anvendelse som medikamenter.
IT1261958B (it) 2-(sostituite immino)-tiazolidine e procedimento per la loro preparazione e loro impiego quali antianginose e/o analgesiche
DK378885A (da) 1-(n-(alfa-amino-alfa-methylacetyl)aminophenyl)-2-aminopropanonderivater, fremgangsmaade til deres fremstilling og deres anvendelse i terapien